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EDITORIALS
Non-treatment of preoperative anaemia is substandard
clinical practice
D. R. Spahn1,* and K. Zacharowski2
1 University of Zürich and University Hospital Zürich, Rämistasse 100, CH-8091 Zürich, Switzerland, and
2 Department of Anaesthesiology, Intensive Care Medicine & Pain Therapy, University Hospital Frankfurt, Frankfurt,
Germany
*Corresponding author. E-mail: donat.spahn@usz.ch
It is well known that preoperative anaemia is frequent and asso-
ciated with increased mortality and morbidity, even if only mild
anaemia is present.1 2 In addition, preoperative anaemia is one of
the most signiﬁcant risk factors in subsequent red blood cell
transfusion,3 which in itself has adverse effects on mortality
and morbidity.4 Therefore, unmanaged preoperative anaemia is
a contraindication for elective surgery.4
In this edition of the British Journal of Anaesthesia, Muñoz and
colleagues5 rightly alerted the medical community, reporting
that preoperative anaemia is often left untreated. The paradox
of known negative consequences of untreated anaemia and cur-
rent practice is explained by the presentation of 10 widely held
misconceptions. Moreover, we identiﬁed two additional reasons
why physicians are still hesitating to treat preoperative anaemia
systematically. First, the World Health Organization’s deﬁnition
of anaemia with a haemoglobin concentration of <120 g litre−1
in women and <130 g litre−1 in men is not sufﬁciently known
by the majority of physicians. Furthermore, the notion that
very mild forms of anaemia (haemoglobin values between 100–
120 and 100–130 g litre−1, respectively) result in adverse clinical
outcomes, such as increased mortality and a long list of compli-
cations,1 2 is also not well known. Second, there may be reluc-
tance by some physicians to treat preoperative anaemia
actively, because of the fact that they themselves will be held re-
sponsible for any adverse events occurring thereafter. In con-
trast, a perioperative transfusion in a patient who is anaemic
before surgery is considered by most an inevitable event, for
which medical staff cannot be held responsible. Therefore,
some physicians prefer not to be involved in treating
preoperative anaemia. We hope that the refuting by Muñoz and
colleagues5 of 10 widely held misconceptions helps pave the
way to widespread treatment of preoperative anaemia.
A consortium of four large German University Hospitals
(Frankfurt, Münster, Bonn, and Kiel) is engaged in the concept
of patient blood management (PBM). The Frankfurt group has
shown how to target and implement treatment of preoperative
anaemia (ClinicalTrials.gov Identiﬁers: NCT01820949 and
NCT02147795). Their investigation clearly highlights ﬁve key suc-
cess factors (Table 1) for implementing a comprehensive pre-
operative anaemia treatment programme. The ﬁrst factor,
which is clearly themost important, was establishing a dedicated
interdisciplinary PBM steering committee, with preoperative an-
aemia treatment being the ﬁrst pillar of PBM.4 Second, the inclu-
sion and support of senior hospital management is of utmost
importance. Only with this support can the necessary reorgan-
ization of the preclinical procedures and structures be implemen-
ted. Additionally, the understanding of surgical and medical
disciplines is crucial to the management and treatment of pre-
operative anaemia. Last, but not least, focusing our efforts on
the knowledge of how operations are regularly performed in an-
aemic patients, who frequently require allogeneic red blood cell
transfusions, is also essential (www.patientbloodmanagement.
eu). Such favourable hospital conditions and improvements can
be achieved only by continuous education over years and through
the coordination of a dedicated interdisciplinary PBM steering
committee. Should your hospital not yet have the aforemen-
tioned structure, then becoming a leader in PBM and establishing
a steering committee is the way forwards.
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Other centres have also succeeded in implementing treat-
ment of preoperative anaemia. Theusinger and colleagues6 con-
tacted the primary physician of each patient found to be anaemic
before surgery. These patients were to undergomajor orthopaed-
ic surgery (n=8871), with suggested treatment of anaemia using
erythropoietin α, i.v. iron, vitamin B12 and folic acid. Despite the
fact that not all patients who were anaemic before surgery were
treated, the incidence of anaemia on the day of operation de-
creased from 15 to 10% (P<0.01) and total allogeneic transfusion
rate reduced from20 to 10% (P<0.01). Short-term treatment of pre-
operative anaemiawith erythropoietin and i.v. iron has also been
shown to be successful in orthopaedic7 and cardiac surgery.8
Likewise, a group of four Spanish hospitals recently published
their success in short-term preoperative treatment of anaemia
with erythropoietin and i.v. iron in 2547 patients undergoing
hip and knee arthroplasty or surgery for hip fracture.9 They
could decrease the allogeneic transfusion rate from 37 to 24%
(P<0.01), the postoperative infection rate from 12 to 8% (P<0.01),
and the length of hospital stay from 12 to 11 days (P<0.01). In pa-
tients undergoing surgery for hip fracture, the 30 day mortality
was reduced from 9 to 5% (P<0.01).
Through sound scientiﬁc evidence, they disproved 10miscon-
ceptions of perioperative anaemia treatment. Moreover, this
medical need can be met with successful treatment options.
Therefore, we conclude that there is no reason why treatment
of preoperative anaemia anaemia should not bewidely practised.
Untreated preoperative anaemia is indeed a contraindication for
elective surgery, and failure to treat preoperative anaemia is sub-
standard clinical practice.
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Early cryoprecipitate for trauma patients is feasible,
but will it improve outcome?
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In this issue of BJA, Curry and colleagues1 demonstrate the feasi-
bility of administering cryoprecipitate as a ﬁbrinogen sourcewith-
in 90min of admissionof traumapatients. This study is important
because cryoprecipitate contains ﬁbrinogen and ﬁbronectin,
which are critical to clotting; data are variable on theneed for cryo-
precipitate in trauma patients, and no randomized controlled
trials looking at the administration of ﬁbrinogen concentrate or
cryoprecipitate in traumapatientshave beenperformed.However,
the completion of the randomized clinical trial on the early use of
cryoprecipitate is needed before implementation of this practice.
Trauma patients receive plasma, which also contains ﬁbrinogen
and ﬁbronectin, but at lower amounts and not in therapeutic
doses. In some countries, prothrombin complex concentrates are
used, which contain some but not all of the clotting factors. Also,
ﬁbrinogen concentrates are being used in trauma patients and re-
quire less volume for administration.
Fibrinogen (factor I) is a 340 kDa protein comprised of two sets
of disulﬁde-bridged Aα, Bβ and γ chains. Thrombin cleavage of ﬁ-
brinopeptide A from the Aα chains creates ﬁbrin, which poly-
merizes and forms the proteinaceous structural basis for blood
clots.2 As such, maintaining adequate ﬁbrinogen concentrations
in bleeding patients seems to be a rational objective. However,
our understanding of what constitutes an adequate concentra-
tion in a bleeding patient, how to determine ﬁbrinogen concen-
trations rapidly and meaningfully, and what products to use for
replacement is relatively poor. 3 4 A 2013 review in the Cochrane
Collaboration examining the use of ﬁbrinogen concentrates in
bleeding patients found only six randomized controlled trials
(248 subjects), of which two hadmortality data.5 While they con-
cluded that there was a suggestion of beneﬁt on reduction of red
blood cell (RBC) transfusions, the authors were unable to draw
any conclusions onmortality. Interestingly, the studies reviewed
showed no effect on other outcomes, including thrombotic ad-
verse events. A systematic review of ﬁbrinogen concentrate in
trauma revealed 12 articles, including a single prospective
study.6 Again, conclusions by the authors were limited, but sug-
gested a reduction in the use of RBC transfusions in this setting.
Taken together, these studies suggest that administration of ﬁ-
brinogen may result in earlier haemorrhage control.
Given that 40% of trauma-relatedmortality is attributable toun-
controlled bleeding, a deeper understanding and optimization of ﬁ-
brinogen supplementation is of great interest. There has been a
substantialfocusontheearlyadministrationofplasmaandplatelets
(plasma:platelet:RBC transfusion ratio); a ratio of 1:1:1 compared
with 1:1:2 did not demonstrate improved survival, but showed that
more plasma and platelets help to achieve earlier haemostasis (al-
though therewasno decrease in the use of RBC transfusionswithin
thetwogroups).7However,cryoprecipitatehasnotbeenaswellstud-
ied. Indeed, ﬁbrinogen deﬁciency (as deﬁned by concentrations
below 100mg dl−1) develops early in trauma.8 The lower amount of
ﬁbrinogen administration via blood products, including whole
blood, plasma, and cryoprecipitate, and deﬁned as ﬁbrinogen:RBC
ratio hasbeen associatedwithhighermortality inmilitary trauma,9
alowercryoprepitate:RBCratiohasbeenassociatedwithhighermor-
tality in civilian trauma,10 and data from an observational cohort
studyrelateslowﬁbrinogenatadmissiontohighertraumamortality
at 24 h and 28 days.11 These studies indicate that increasing ﬁbrino-
gen concentrations in trauma patientsmay be beneﬁcial. However,
there are no randomized trials looking speciﬁcally at ﬁbrinogen or
cryoprecipitate in trauma patients. It is from this perspective that
the study by Curry and colleagues,1 published in this issue of the
BJA, takes on importance.
In their study, Curry and colleagues1 performed a feasibility
study to determine whether it is possible to administer cryopre-
cipitate as a ﬁbrinogen source within 90 min of admission of
trauma patients. This is operationally complex because cryopre-
cipitate must be thawed and then delivered and cannot be stored
for more than 6 h. Secondary objectives included laboratory
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